Market Place
Sourcing Support
Entasis lands first antibiotic approval eight years after spinning out of AZ
25 May 2023 //
ENDPTS
Adcomm unanimously recommends Entasis` bacterial pneumonia
17 Apr 2023 //
ENDPTS
Entasis Presents Safety Data from Landmark PIII ATTACK Trial at IDWEEK 2022
19 Oct 2022 //
GLOBENEWSWIRE
Entasis , a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR
12 Oct 2022 //
GLOBENEWSWIRE
Innoviva Completes Acquisition of Entasis Therapeutics
11 Jul 2022 //
BUSINESSWIRE
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Tx
08 Jul 2022 //
BUSINESSWIRE
Entasis Presents Data on Sulbactam-Durlobactam & ETX0462 at 2022 ASM
09 Jun 2022 //
GLOBENEWSWIRE
Innoviva to acquire Entasis Therapeutics for $2.20/share
24 May 2022 //
SEEKING ALPHA
Entasis Therapeutics Announces Q1 2022 Financial Results
27 Apr 2022 //
GLOBENEWSWIRE
Entasis Presents Efficacy and Safety Data from Landmark Phase 3
26 Apr 2022 //
GLOBENEWSWIRE
Entasis Tx Presents SUL-DUR Topline Data from PIII ATTACK Trial at ECCMID
18 Apr 2022 //
GLOBENEWSWIRE
Entasis Therapeutics Announces Year End 2021 Financial Results
03 Mar 2022 //
GLOBENEWSWIRE
Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.
02 Feb 2022 //
PRESS RELEASE
Entasis Therapeutics to Report Third Quarter 2021 Results
30 Oct 2021 //
PRESS RELEASE
Entasis antibiotic beats last resort treatment in phase 3 trial
20 Oct 2021 //
YAHOOFINANCE
Context Therapeutics Announces Pricing of Initial Public Offering
19 Oct 2021 //
GLOBENEWSWIRE
Entasis announces +ve topline results for sulbactam-durlobactam (SUL-DUR)Ph3
18 Oct 2021 //
BIOSPACE
Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual GHC
23 Sep 2021 //
GLOBENEWSWIRE
Entasis up 14% following publication on new antibiotic class drug candidate
16 Sep 2021 //
SEEKINGALPHA
Profile of Entasis Therapeutics ETX0462 Candidate Published in Journal Nature
16 Sep 2021 //
GLOBENEWSWIRE
Entasis Therapeutics to Report Second Quarter 2021 Results
05 Aug 2021 //
GLOBENEWSWIRE
Entasis Therapeutics to Participate in the 2021 Wedbush PacGrow Conference
04 Aug 2021 //
GLOBENEWSWIRE
Entasis Introduces ETX0462 Targeting Multidrug-Resistant Gram-ve Pathogens
01 Jul 2021 //
GLOBENEWSWIRE
Entasis Therapeutics announces Positive Data for ETX0462 at World Microbe Forum
18 Jun 2021 //
GLOBENEWSWIRE
Entasis Completes Initial Closing of $20M Private Placement with Innoviva
04 May 2021 //
GLOBENEWSWIRE
Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program
26 Jan 2021 //
GLOBENEWSWIRE
Fortress Biotech takes out $60M loan for debt purposes
28 Aug 2020 //
ENDPTS
Entasis Therapeutics Awarded Contract from National Institutes of Health
06 Jul 2020 //
GLOBENEWSWIRE
Entasis Therapeutics Completes Initial Closing of $35M Private Placement
22 Apr 2020 //
GLOBENEWSWIRE
Ipsen grabs new R&D lead as Shire`s neuro head leaves amid Takeda takeover
06 Nov 2019 //
FIERCE BIOTECH
AstraZeneca spinout Entasis nabs Shire exec as CMO
02 Nov 2019 //
FIERCE BIOTECH
Novo Holdings` antibiotic resistance fund backs 3 biotechs
21 Jan 2019 //
FIERCE BIOTECH
Entasis Therapeutics and the Global Antibiotic Research & Development Partnership
22 Nov 2018 //
PRESS RELEASE
Entasis Therapeutics Announces Zoliflodacin Phase 2 Results Published in NEJM
07 Nov 2018 //
GLOBENEWSWIRE
AstraZeneca-backed Entasis Therapeutics joins the IPO
26 Sep 2018 //
ENDPTS
Entasis Therapeutics Readies $75 Million IPO Plan
20 Sep 2018 //
SEEKING ALPHA
AztraZeneca-backed biotech Entasis Therapeutics files for an $86 million IPO
18 Aug 2018 //
NASDAQ
Entasis Therapeutics Highlights Positive Phase 1 Data for ETX2514 at IDWeek 2017
09 Oct 2017 //
BUSINESSWIRE
AstraZeneca PLC Antibiotics Alums Emerge at Biotech Spinout Entasis Therapeutics
01 Jul 2015 //
BIOSPACE
